Replies to post #44184 on Lans Holdings Inc (fka LAHO)

[ApollyonZ]

$LAHO GSCG partner Magellan $7B.. acquires+++

adult stem cell technology Arteriocyte Medical Systems Inc., created by Arteriocyte Inc. and DW Healthcare Partners, acquires Magellan Platelet Gel Business

http://blog.case.edu/case-news/2007/11/08/magellan

Global Stem Cells Group and Adimarket to Represent Magellan in Latin America and Middle East.

Magellan Autologous Platelet Separator in Latin America and Middle East.

..Developed by Arteriorcyte Medical Systems, a leading medical device company headquartered in Hopkinton, Mass., the Magellan Autologous Platelet Separator is a high-tech, automated dual spin processing system designed for use in clinical laboratories or intraoperatively at the point-of-care for safe and rapid preparation of high-quality, platelet-rich plasma (PRP) as well as platelet poor plasma (PPP).


https://www.prunderground.com/global-stem-cells-group-and-adimarket-to-represent-magellan-in-latin-america-and-middle-east/00112628/
https://www.stemcellsgroup.com/category/press-releases/page/7/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149417726

..Platelet-rich plasma (PRP) is blood plasma that has been enriched with platelets. It holds promise for clinical use in areas such as wound healing and regenerative medicine, including bone regeneration...

https://www.ncbi.nlm.nih.gov/pubmed/24748436

Autologous Platelet Gel Applications During Cardiovascular Surgery: Effect on Wound Healing

CONCLUSIONS

In this pilot study, we found support that chest and leg pain were decreased in the experimental group, and we observed that the experimental group had less bruising
..
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682529/
https://www.istobiologics.com/resources/magellan-ifu

Magellan will acquire Senior Whole Health for approximately $400 million cash.

https://www.businesswire.com/news/home/20171031005298/en/Magellan-Health-Closes-Acquisition-Senior-Health

Magellan.. is affirming its 2019 earnings guidance ranges, but modestly lowering the revenue guidance to a range of $7.0 to $7.2 billion.

https://ir.magellanhealth.com/news-releases/news-release-details/magellan-health-reports-first-quarter-2019-financial-results

Magellan Health

will pay a base price of $210 million and a potential earn-out of $75 million to the owners of ICORE, all of whom are members of the management team.

https://www.fdanews.com/articles/88498-magellan-health-to-acquire-icore-healthcare

Magellan Health to Acquire Veridicus Holdings, LLC

https://ir.magellanhealth.com/news-releases/news-release-details/magellan-health-acquire-veridicus-holdings-llc


$LAHO GSCG Magellan Future of Medicine$$$